Core Insights - Shanghai Yizhong (688091) reported a significant increase in revenue and profit for 2025, with total revenue reaching 317 million yuan, representing a year-on-year growth of 82.72% [1] - The net profit attributable to shareholders was 64.132 million yuan, showing an impressive year-on-year increase of 819.42% [1] - The company's core product, injectable paclitaxel polymer micelles, was officially included in the national medical insurance directory in 2025, which greatly enhanced market access and the number of patients using the product, driving revenue and profit growth for the year [1]

Core Viewpoint - Shanghai Yizhong (688091.SH) reported significant growth in its 2025 financial performance, driven by the inclusion of its core product, paclitaxel polymer micelles, in the national medical insurance catalog [1] Financial Performance - The company achieved an operating revenue of 317 million yuan in 2025, representing a year-on-year increase of 82.72% [1] - The net profit attributable to the parent company was 64.132 million yuan, showing a remarkable year-on-year growth of 819.42% [1] Product Impact - The inclusion of paclitaxel polymer micelles in the national medical insurance catalog significantly boosted market access and the number of patients using the product, contributing to the overall revenue and profit growth for the year [1]

上海谊众(688091.SH)发布2025年年度业绩预告公告，预计2025年度实现归属于母公司所有者的净利润 为6,000万元到7,000万元;与上年同期相比，增长760.18%到903.54%。 本期业绩变化的主要原因：公司核心产品注射用紫杉醇聚合物胶束(以下简称"紫杉醇胶束")于2025年正 式纳入国家医保目录，在市场准入与用药人数上大幅提高，带动了公司全年营收与利润相较于2024年显 著增长。 ...